The acquisition of Healint aligns with Aptar Digital Health’s strategy to broaden its portfolio in neurology and strengthen its global footprint for digital health deployment
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
Global Initiative on Digital Health (GIDH) was launched by the WHO and the Government of India during the G20 Health Working Group meeting in Gandhinagar last year
Project achieves 30% reduction in hospital acquired infections and 24% reduction in the incidence of multi-drug resistant organisms
The fast pace of construction of AIIMS Jammu whose foundation stone laying to inauguration took only 5 years highlights the commitment of the Government
The project aims at screening the general health condition of the students enrolled in classes 6th to 12th.
The preventive and promotive approach of our traditional health care systems has played a significant role in modern age today
The acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus
IOL Chemicals and Pharmaceuticals’ product approved by CDE of NMPA, China
The acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting antithymic stromal lymphopoietin (TSLP) monoclonal antibody
Commercialization of rPEG lipids designed to improve immunogenicity profile for nucleic acid delivery
The agreement sets terms under which POC will manufacture the product or receive royalties
AIIMS Rewari is a 750-bed hospital complex which includes a 100 seat medical college, a 60 seat nursing college, a 30-bed AYUSH block
The restructuring aims to create synergies across the business and strengthen capital structure
Through our research, we aim to ultimately provide new options for our customers to treat life-threatening infections in livestock
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
It is indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation
iSolveSM information on demand is the result of our focus on customer relationship
Subscribe To Our Newsletter & Stay Updated
